Peptide questions · Follistatin-344
Follistatin-344 side effects: what studies and users report
Reviewed Evidence: EmergingPublished by PepVault
The side effects most commonly reported for Follistatin-344 are injection site reaction, mild fatigue and joint discomfort; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The one clear human harm signal for injected follistatin-344 is an eye one.
What is commonly reported with Follistatin-344
- Injection site reaction
- Mild fatigue
- Joint discomfort
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 13) |
|---|---|
| Injection site reaction | 4: Sermorelin, Tesamorelin, IGF-1 LR3, PEG-MGF |
| Mild fatigue | None: listed for Follistatin-344 alone |
| Joint discomfort | None: listed for Follistatin-344 alone |

Which Follistatin-344 side effects the growth hormone group shares
Across the 14 growth hormone compounds in the library, the effects listed most often are water retention (10 of 14), headache (5 of 14), injection site reaction (5 of 14) and fatigue (4 of 14). Follistatin-344 shares 1 of its 3 listed effects with at least one other growth hormone compound; mild fatigue and joint discomfort are listed for Follistatin-344 alone.
What the Follistatin-344 safety notes say
The library’s safety note
The one clear human harm signal for injected follistatin-344 is an eye one. Eleven male bodybuilders, average age 37, turned up at a single Turkish clinic with central serous chorioretinopathy — fluid under the retina, which shows up as blurred, dim or distorted central vision — after injecting whole 1 mg vials of follistatin-344 under the skin of the abdomen. Ten had it in one eye, one in both. In the eight who had injected once, the fluid cleared on its own over about 2.3 months; the three who had injected repeatedly had recurrences. New blurring or a dim or warped patch in the middle of your vision is worth an eye exam rather than waiting. Beyond that, there is no human safety data on the injected peptide: no trial, no pharmacokinetics, no toxicology. The gene-therapy trials are reassuring as far as they go — in six men with Becker muscular dystrophy given the FS344 gene into the quadriceps, blood counts, liver, kidney and the pituitary hormones FSH, LH, testosterone and estrogen stayed normal through a year, and no adverse events were attributed to the transfer — but that is a local gene delivery of one isoform, not a systemic protein injection. Follistatin is also a reproductive-axis protein, which is exactly why those trials picked the FS344 splice form and watched FSH. Product identity is a live problem: of 17 black-market products labelled follistatin, nine actually contained it, all nine His-tagged with a high share of clumped protein, and some of the rest contained MGF or GHRP-2 instead. For athletes: myostatin-binding proteins, follistatin named explicitly, are prohibited at all times under the 2026 WADA list (S4.3). Discuss with your clinician; this is an unapproved compound whose human record is one adverse-event series.
The library’s interaction note
No interaction data exists for injected follistatin. Two mechanistic points are worth a clinician conversation. First, follistatin binds activins, which help regulate the pituitary's FSH output; the gene-therapy trials deliberately chose the splice form least able to suppress it and still monitored FSH, LH, testosterone and estrogen, so anyone on fertility or hormone treatment is layering onto a system this protein touches. Second, its muscle effect in mice needs the IGF-1 receptor, Akt and mTOR, which is the same pathway GH, IGF-1 analogues and insulin act on — the reason it is stacked with them, and the reason nothing about that combination has been studied. Discuss any prescription medications with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the Follistatin-344 reports come from
The library rates the evidence on Follistatin-344 as emerging: mostly preclinical, with limited human data.
Of the library’s 7 research notes on Follistatin-344, 1 rest on randomized trials, 2 on clinical data, 1 on animal studies and 3 on community reports.
Our 2 study pages on Follistatin-344: 1 observational study and 1 clinical trial.
So Follistatin-344 has controlled trials in people to set its listed effects against.
What our Follistatin-344 study pages report on safety
Follistatin-344 gene therapy: walk gains in some Becker patients
Clinical trial, human, 2015: No adverse effects were seen, and muscle samples showed less endomysial fibrosis (scarring between muscle fibers), fewer fibers with central nuclei, more normal fiber sizes and muscle hypertrophy (growth), most of all at the high dose. This small early human trial of follistatin delivered as gene therapy found walking gains in some people with Becker muscular dystrophy and no adverse effects, but it says nothing directly about injected follistatin peptides.
Questions people ask
What are the side effects of Follistatin-344?
The side effects most commonly reported for Follistatin-344 are injection site reaction, mild fatigue and joint discomfort; the library’s evidence on it includes controlled trials in people.
Do Follistatin-344’s side effects come from human studies?
The library rates the evidence on Follistatin-344 as emerging, and the library’s evidence on it includes controlled trials in people.
Which Follistatin-344 side effects are its own?
Among the growth hormone compounds, the library lists mild fatigue and joint discomfort for Follistatin-344 alone.
Does Follistatin-344 interact with other medicines?
The library’s interaction note on Follistatin-344 begins: No interaction data exists for injected follistatin.